Skip to main content
. 2014 Apr 21;20(15):4276–4287. doi: 10.3748/wjg.v20.i15.4276

Table 4.

MicroRNA biomarkers in the blood and stool of colorectal cancer patients

Markers Sample Sensitivity Specificity Ref.
Blood
miR-21 186 CRC 76.8%-82.8% 81.1%-90.6% [77]
43 A 91.9% 81.1%
53 controls
miR-601/ miR-760 90 CRC 83.3% 69.1% [78]
48 AA 72.1% 62.1%
58 controls
miR-21 30 CRC 90.0% 90.0% [79]
30 controls
miR-29a 258 plasma sample 75.0% 75.0% [80]
miR-141 102 CRC 77.1%-90.9% 77.1%-89.7% [81]
miR-92a 120 CRC 84.0% 71.2% [82]
37 AA 64.9% 81.4%
59 controls
miR-29a 120 CRC 69.0% 89.1% [82]
37 AA 62.2% 84.70%
59 controls
miR-221 103 CRC 86.0% 41.0% [83]
37 controls
miR-17-3P 90 CRC 64.0% 70.0% [84]
50 controls
miR-92a 90 CRC 89.0% 70.0% [84]
50 controls
Stool
miR-21 88 CRC 55.7% 73.3% [85]
57 polyps 43.9%
101 controls
miR-92a 88 CRC 71.6% 73.3% [85]
57 polyps 56.1%
101 controls
miR-144* 75 CRC 74.0% 87.0% [86]
miR 17-92 cluster 197 CRC 69.5% 81.5% [87]
119 controls
miR-135 197CRC 46.2% 95.0% [87]
119 controls
miR-21 197 CRC 14.7% 91.6% [87]
119controls
miR-92a 59 CRC 50.0% 80.0% [88]
74 controls
miR-21 59 CRC 50.0% 83.0% [88]
74 controls

A: Adenoma; CRC: Colorectal cancer.